Form 4: Travere Therapeutics Director John A. Orwin Acquires Shares and Options

Director John A. Orwin acquired 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc. on May 15, 2025, according to a Form 4 filing.

Summary

• On May 15, 2025, John A. Orwin, a director of Travere Therapeutics, Inc., acquired 6,500 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Orwin directly owns 35,375 shares of common stock.
• Orwin also acquired 19,500 stock options with an exercise price of $21.15.
• These options vest over a one-year period and expire on May 15, 2035.
• The acquisition was an automatic equity grant under the company's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an equity grant to a director, which is neither particularly positive nor negative.

Positives

• The director's acquisition of shares and options could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Director compensation packages often include stock options and equity grants to align the interests of directors with those of shareholders.
• The vesting schedule of one year is a fairly standard practice for equity awards.

Stakeholder Impact

• The transaction has a minor impact on shareholders, as it increases the number of shares outstanding and aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Travere Therapeutics, Director, John A. Orwin, Stock Options, Equity Grant, Form 4, Beneficial Ownership